VITL
Builds software to overhaul cash-pay clinic prescribing workflows, capitalizing on demand driven by the GLP-1 medication boom.
Overview
VITL builds software aimed at overhauling prescribing workflows in cash-pay clinics, targeting clinics and providers responding to the surge in GLP-1 demand. The company focuses on streamlining how cash-pay healthcare operators manage and deliver high-demand therapies within their existing care and payment models. VITL disclosed an undisclosed $8M raise on 2026-03-25 (press coverage characterized the amount as $7.5M), bringing total known funding to $8M. The firm positions itself as a niche operational vendor for cash-pay clinics seeking solutions to handle rapid patient demand tied to the GLP-1 market boom.
Funding History
Riding the GLP-1 boom, VITL lands $7.5M to overhaul cash-pay clinic prescribing.
Frequently Asked Questions
- How much funding does AI Funding track for VITL?
- AI Funding tracks $8M for VITL across 1 funding round in this database.
- Who are VITL's investors?
- VITL's investors include SignalFire.
- What does VITL do?
- VITL builds software aimed at overhauling prescribing workflows in cash-pay clinics, targeting clinics and providers responding to the surge in GLP-1 demand. The company focuses on streamlining how cash-pay healthcare operators manage and deliver high-demand therapies within their existing care and payment models. VITL disclosed an undisclosed $8M raise on 2026-03-25 (press coverage characterized the amount as $7.5M), bringing total known funding to $8M. The firm positions itself as a niche operational vendor for cash-pay clinics seeking solutions to handle rapid patient demand tied to the GLP-1 market boom.
- Where is VITL headquartered?
- VITL is headquartered in San Francisco, CA.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.